阻断CX3CL1/CX3CR1通路抑制系统性硬化症小鼠模型皮肤炎症、纤维化和血管损伤的进展
该研究在培养的人真皮成纤维细胞及博来霉素诱导和生长因子诱导的系统性硬化症(SSc)小鼠模型中,评估抗CX3CL1单克隆抗体的临床前疗效与机制。结果显示抗CX3CL1治疗可抑制TGFβ1诱导的成纤维细胞Smad3磷酸化及I型胶原和纤连蛋白1表达,并减轻博来霉素诱导的皮肤厚度、胶原含量和毛细血管丢失,但对已建立的皮肤纤维化无显著改善。结论提示抗CX3CL1单抗可能成为治疗SSc等炎症驱动性皮肤纤维化疾病早期皮肤纤维化的新方法。
要点
- 抗CX3CL1单抗抑制TGFβ1刺激的真皮成纤维细胞Smad3磷酸化及I型胶原、纤连蛋白1表达。
- 在博来霉素模型中,抗CX3CL1单抗或CX3CR1缺陷减轻皮肤厚度、胶原含量和毛细血管丢失。
- 治疗减少皮肤CX3CR1+细胞、巨噬细胞和CD3+细胞浸润,但未显著改善已建立的皮肤纤维化。
核心结论
- 抗CX3CL1单克隆抗体可能成为治疗SSc等炎症驱动性皮肤纤维化疾病早期皮肤纤维化的新方法。
研究设计与样本
- 研究使用培养的人真皮成纤维细胞评估抗CX3CL1单抗的直接效应,并采用博来霉素诱导和生长因子诱导的SSc小鼠模型。
主要发现
- 抗CX3CL1单抗显著抑制TGFβ1刺激的真皮成纤维细胞Smad3磷酸化(P < 0.05)及I型胶原和纤连蛋白1表达(P < 0.01)。
- 博来霉素模型中小鼠每日皮下注射博来霉素增加血清CX3CL1水平(P < 0.05)并增强病灶CX3CL1表达。
- 同时给予抗CX3CL1单抗或CX3CR1缺陷显著抑制博来霉素引起的真皮厚度、胶原含量和毛细血管丢失(P < 0.05)。
- 抗CX3CL1单抗治疗显著减少皮肤CX3CR1+细胞、巨噬细胞(炎症性和M2样亚群)及CD3+细胞浸润(P < 0.05),并降低促纤维化分子胸腺基质淋巴细胞生成素和分泌型磷蛋白1的皮肤表达(P < 0.05)。
- 抗CX3CL1单抗未显著减轻已建立的皮肤纤维化;在生长因子诱导模型中,同时给予抗mCX3CL1单抗显著减轻TGFβ和结缔组织生长因子连续皮下注射诱导的皮肤纤维化(P < 0.01)。
关键数值与推荐
- 博来霉素模型中,抗CX3CL1单抗或CX3CR1缺陷使博来霉素引起的真皮厚度、胶原含量和毛细血管丢失的抑制达统计学显著(P < 0.05)。
- 抗CX3CL1单抗抑制TGFβ1刺激的真皮成纤维细胞Smad3磷酸化(P < 0.05)及I型胶原和纤连蛋白1表达(P < 0.01)。
- 生长因子诱导模型中,抗mCX3CL1单抗显著减轻TGFβ和结缔组织生长因子诱导的皮肤纤维化(P < 0.01)。
临床怎么用
- 抗CX3CL1单抗可能适用于炎症驱动性皮肤纤维化疾病如SSc的早期干预,而非已建立的皮肤纤维化。
局限性
- 研究为临床前小鼠模型和体外细胞实验,尚未在人体中验证疗效与安全性。
- 抗CX3CL1单抗未显著减轻已建立的皮肤纤维化,提示对晚期纤维化病变作用有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the preclinical efficacy and mechanism of action of an anti-CX3 CL1 monoclonal antibody (mAb) in systemic sclerosis (SSc). METHODS: Cultured human dermal fibroblasts were used to evaluate the direct effect of anti-CX3 CL1 mAb on fibroblasts. In addition, bleomycin-induced and growth factor-induced models of SSc were used to investigate the effect of anti-CX3 CL1 mAb on leukocyte infiltration, collagen deposition, and vascular damage in the skin. RESULTS: Anti-CX3 CL1 mAb treatment significantly inhibited Smad3 phosphorylation (P < 0.05) and expression of type I collagen and fibronectin 1 (P < 0.01) in dermal fibroblasts stimulated with transforming growth factor β1 (TGFβ1). In the bleomycin model, daily subcutaneous bleomycin injection increased serum CX3 CL1 levels (P < 0.05) and augmented lesional CX3 CL1 expression. Simultaneous administration of anti-CX3 CL1 mAb or CX3 CR1 deficiency significantly suppressed the dermal thickness, collagen content, and capillary loss caused by bleomycin (P < 0.05). Injection of bleomycin induced expression of pSmad3 and TGFβ1 in the skin, which was inhibited by anti-CX3 CL1 mAb. Further, the dermal infiltration of CX3 CR1+ cells, macrophages (inflammatory and alternatively activated [M2-like] subsets), and CD3+ cells significantly decreased following anti-CX3 CL1 mAb therapy (P < 0.05), as did the enhanced skin expression of fibrogenic molecules, such as thymic stromal lymphopoietin and secreted phosphoprotein 1 (P < 0.05). However, the treatment did not significantly reduce established skin fibrosis. In the second model, simultaneous anti-mCX3 CL1 mAb therapy significantly diminished the skin fibrosis induced by serial subcutaneous injection of TGFβ and connective tissue growth factor (P < 0.01). CONCLUSION: Anti-CX3 CL1 mAb therapy may be a novel approach for treating early skin fibrosis in inflammation-driven fibrotic skin disorders such as SSc.
引用
- Luong VH, Utsunomiya A, Chino T, et al. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX3 CL1/CX3 CR1 Pathway in Experimental Mouse Models of Systemic Sclerosis. Arthritis Rheumatol. 2019. PMID: 31173491. doi:10.1002/art.41009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。